XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Options
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock Options

14. Stock Options

 

The Company has a stock option plan (“Plan”). The purpose of this Plan is to provide additional incentives to key employees, officers, directors and consultants of the Company and its subsidiaries in order to help attract and retain the best available personnel for positions of responsibility and otherwise promote the success of the Company’s business. It is intended that options issued under this Plan constitute non-qualified stock options. The general terms of awards under the option plan are that 100% of the options granted will vest the year following the grant. The maximum term of options granted is 5 years and the exercise price for all options are issued for not less than fair market value at the date of the grant.

 

The following table summarizes the Company’s stock option activities for the year ended December 31, 2020 and the three-month period ended March 31, 2021:

 

    Number of shares     Exercise price
per share
    Weighted average exercise price  
                   
Balance, December 31, 2019     635,000     $ 0.75 – 1.75     $ 1.35  
Granted     172,000     $ 2.44     $ 2.44  
Cancelled or expired     (13,000 )   $ 2.44 – 3.46     $ 2.75  
Exercised     (45,000 )   $ 0.75 – 1.05     $ 0.88  
Balance, December 31, 2020     749,000     $ 0.75 – 4.13     $ 2.42  
Cancelled or expired     (27,799 )   $ 1.42 – 3.46     $ 2.45  
Exercised     (55,201 )   $ 0.75 – 3.46     $ 1.55  
Balance, March 31, 2021     666,000     $ 1.42 – 4.13     $ 2.66  
Exercisable, March 31, 2021     423,000     $ 1.42 – 4.13     $ 2.44  

 

The weighted average remaining contractual life of options outstanding is 3.6 years.

 

The fair value of each option grant is calculated using the following weighted average assumptions:

 

    2020  
       
Expected life – years     3.0  
Interest rate     0.37 %
Volatility     70.14 %
Weighted average fair value of options granted   $ 1.12  

 

The Company did not grant any options during the three months ended March 31, 2021 or 2020. Options granted in previous quarters resulted in expenses in the amount of $13,065 for consultants (2020 - $11,272) and $26,524 for employees (2020 - $18,310) during the quarter ended March 31, 2021. There were 32,000 employee and 23,201 consultant stock options exercised during the three months ended March 31, 2021 (2020 – 15,000 employee and 10,000 consultant stock options).

 

As of March 31, 2021, there was approximately $129,991 of compensation expense related to non-vested awards. This expense is expected to be recognized over a weighted average period of 1 year.

 

The aggregate intrinsic value of vested options outstanding at March 31, 2021 is $578,660 (2020 – $nil).